Brokerages expect DURECT Co. (NASDAQ:DRRX) to report earnings per share (EPS) of ($0.03) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for DURECT’s earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at ($0.02). DURECT reported earnings of $0.04 per share in the same quarter last year, which would indicate a negative year over year growth rate of 175%. The company is expected to issue its next quarterly earnings report on Wednesday, November 7th.

According to Zacks, analysts expect that DURECT will report full year earnings of ($0.19) per share for the current fiscal year, with EPS estimates ranging from ($0.20) to ($0.17). For the next year, analysts forecast that the business will report earnings of ($0.18) per share, with EPS estimates ranging from ($0.22) to ($0.12). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow DURECT.

DURECT (NASDAQ:DRRX) last announced its quarterly earnings data on Wednesday, August 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. DURECT had a negative net margin of 2.04% and a negative return on equity of 4.27%. The company had revenue of $3.41 million during the quarter, compared to analysts’ expectations of $3.83 million.

A number of equities analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of DURECT in a research note on Tuesday, July 31st. BidaskClub cut shares of DURECT from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $2.50.

Shares of DRRX stock traded down $0.03 during mid-day trading on Monday, reaching $1.11. The company’s stock had a trading volume of 217,600 shares, compared to its average volume of 761,718. DURECT has a 1-year low of $0.75 and a 1-year high of $2.55. The stock has a market cap of $197.64 million, a price-to-earnings ratio of -37.00 and a beta of 0.93. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.36 and a current ratio of 3.60.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of DURECT by 17.8% during the 1st quarter. BlackRock Inc. now owns 11,480,772 shares of the specialty pharmaceutical company’s stock worth $24,568,000 after purchasing an additional 1,733,644 shares in the last quarter. United Services Automobile Association increased its position in shares of DURECT by 1,296.1% during the 2nd quarter. United Services Automobile Association now owns 273,017 shares of the specialty pharmaceutical company’s stock worth $22,379,000 after purchasing an additional 253,461 shares in the last quarter. Millennium Management LLC increased its position in shares of DURECT by 153.6% during the 1st quarter. Millennium Management LLC now owns 686,685 shares of the specialty pharmaceutical company’s stock worth $1,470,000 after purchasing an additional 415,925 shares in the last quarter. Mackay Shields LLC acquired a new stake in shares of DURECT during the 1st quarter worth about $367,000. Finally, Alambic Investment Management L.P. acquired a new stake in shares of DURECT during the 2nd quarter worth about $463,000. Institutional investors own 47.80% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand.

Further Reading: Earnings Per Share (EPS)

Get a free copy of the Zacks research report on DURECT (DRRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.